delete Pharmaceutical Benefits Regulations (Amendment)
Unable to review: no regulatory text provided. Title indicates amendment to Pharmaceutical Benefits Regulations, likely modifying subsidy arrangements, pricing controls, or administrative requirements under the PBS framework.
Cannot assess without the actual instrument text. However, pharmaceutical price controls and subsidy schemes distort market signals, reduce supplier incentives, create compliance costs, and typically lead to shortages and reduced innovation. The PBS framework itself represents significant government intervention in pharmaceutical markets, and amendments to these regulations would typically add further distortion rather than remove it.